Nanoparticle Transferrin Targeting Blood-Brain Barrier Crossing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The blood-brain barrier (BBB) poses a significant obstacle for drug delivery to the central nervous system (CNS), as it is impermeable to most solutes, limiting the effectiveness of current treatments for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis, with only a small percentage of small molecule therapeutics able to cross and none of large-molecule therapeutics like monoclonal antibodies or gene therapies.
Innovation Solution
Development of nanoparticles with a targeting agent, such as a ligand specific for brain endothelial cell receptors, conjugated to a linker that dissociates within the cell, allowing the nanoparticle to deliver therapeutic or imaging agents across the BBB by exploiting receptor-mediated transcytosis, using materials like cationic mucic acid polymers, PLGA, or gold cores with pH-sensitive or disulfide linkers for controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional therapeutics are used, then treatment of neurological diseases is attempted, but the BBB prevents crossing of 98% of small molecule therapeutics and essentially 100% of large-molecule therapeutics
Solution Approach 1:
The patent uses transferrin as an intermediary molecule that binds to the nanoparticle surface and exploits the transferrin receptor-mediated transcytosis pathway. The transferrin-transferrin receptor interaction serves as a mediator to transport the nanoparticle across the BBB endothelial cells, converting the nanoparticle into a recognized substrate for cellular uptake and transport mechanisms that naturally cross the barrier.
2Reliability
If receptor-mediated transcytosis is utilized, then BBB crossing is achieved, but the ligand must be specifically bound to the nanoparticle surface
Solution Approach 1:
The nanoparticle is constructed as a composite structure combining a core material (such as PLGA, gold, or iron oxide) with surface-conjugated transferrin molecules. This composite approach allows the nanoparticle to inherit properties from both components: the core provides structural integrity and therapeutic cargo capacity, while the transferrin coating provides BBB-targeting capability through receptor-mediated transcytosis.
3Reliability
If tight junctions between endothelial cells are present, then CNS homeostasis is maintained, but paracellular diffusion of polar molecules, macromolecules and cells is inhibited
Solution Approach 1:
The invention targets the specific local quality of endothelial cells by conjugating transferrin to the nanoparticle surface, which specifically recognizes and binds to transferrin receptors localized on the luminal surface of BBB endothelial cells. This localized targeting enables selective interaction with the transport mechanism at the BBB interface without disrupting the overall tight junction structure and CNS homeostasis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the targeted delivery of therapeutic agents, such as serotonin or dopamine, and imaging agents like Cu64 across the BBB, potentially treating neurological disorders by increasing the accumulation of drugs within the CNS, as demonstrated by improved brain parenchyma access and therapeutic agent delivery.
Implementation Method 1
The BBB is a physical barrier between the CNS parenchyma and vasculature that plays a critical role in maintaining homeostasis within the CNS. Tight junctions exist between endothelial cells that inhibit paracellular diffusion of polar molecules, macromolecules and cells. This forces solute transport into the CNS to occur primarily across individual endothelial cells.
Implementation Method 2
the linker may include a hydrolyzable chemical bond that can be disrupted at low pH to cause disassociation of the ligand from the nanoparticle when the nanoparticle is inside a brain endothelial cell
Implementation Method 3
the linker may include a disulfide bond that can be reduced to cause disassociation of the ligand from the nanoparticle when the nanoparticle is inside a brain endothelial cell
Data Source
AI summary
Described herein are methods of delivering a nanoparticle across the blood brain barrier to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle.